The stock of CorMedix Inc. (NYSEMKT:CRMD) is a huge mover today! The stock increased 6.80% or $0.14 on November 7, hitting $2.2. About 87,048 shares traded hands. CorMedix Inc. (NYSEMKT:CRMD) has declined 33.33% since April 5, 2016 and is downtrending. It has underperformed by 35.29% the S&P500.
The move comes after 8 months positive chart setup for the $83.53M company. It was reported on Nov, 7 by Barchart.com. We have $2.99 PT which if reached, will make NYSEMKT:CRMD worth $30.07 million more.
Analysts await CorMedix Inc. (NYSEMKT:CRMD) to report earnings on November, 10. They expect $-0.15 EPS, down 7.14% or $0.01 from last year’s $-0.14 per share. After $-0.13 actual EPS reported by CorMedix Inc. for the previous quarter, Wall Street now forecasts 15.38% negative EPS growth.
According to Zacks Investment Research, “CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix’s goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications. The Company’s therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy. Its product pipeline includes: CRMD001, a unique formulation Deferiprone which is in development to prevent Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; CRMD002, a diagnostic test for urinary labile iron; CRMD003 (NeutrolinÂ®, an antimicrobial/anticoagulant solution) is in development to prevent Catheter Related Bloodstream Infection; CRMD004, a pressure sensitive gel which has many uses, including extending the benefits of NeutrolinÂ®. CorMedix Inc. is based in Summit, New Jersey.”
Insitutional Activity: The institutional sentiment decreased to 0.54 in Q2 2016. Its down 1.10, from 1.64 in 2016Q1. The ratio dropped, as 18 funds sold all CorMedix Inc. shares owned while 17 reduced positions. 10 funds bought stakes while 9 increased positions. They now own 4.22 million shares or 33.14% less from 6.32 million shares in 2016Q1.
Blackrock Ltd Limited Liability Company accumulated 0% or 7,588 shares. Tci Wealth last reported 5,450 shares in the company. Citigroup accumulated 48 shares or 0% of the stock. Envestnet Asset Mgmt accumulated 0% or 2,000 shares. Credit Suisse Ag last reported 0% of its portfolio in the stock. Blackrock Fund has invested 0% of its portfolio in CorMedix Inc. (NYSEMKT:CRMD). Washington Company last reported 24,750 shares in the company. Barclays Pcl last reported 3,654 shares in the company. Geode Cap Management Limited Com last reported 0% of its portfolio in the stock. Lmr Llp, a United Kingdom-based fund reported 45,320 shares. Vanguard Grp Inc owns 1.11M shares or 0% of their US portfolio. Blackrock Inv Mngmt Ltd Liability reported 5,891 shares or 0% of all its holdings. Bnp Paribas Arbitrage has 0% invested in the company for 23 shares. Moreover, Kanaly Com has 0% invested in CorMedix Inc. (NYSEMKT:CRMD) for 2,570 shares. Raymond James Fincl Services Advsrs Incorporated last reported 0% of its portfolio in the stock.
Insider Transactions: Since May 18, 2016, the stock had 5 buys, and 10 sales for $447,494 net activity. The insider Kaplan Myron bought $34,496. The insider Duffy Matthew sold $126,008. Pfaffle Antony sold $34,656 worth of stock or 12,700 shares. Another trade for 1,475 shares valued at $3,171 was bought by TELLEZ CORA M. $87,958 worth of CorMedix Inc. (NYSEMKT:CRMD) was sold by Lefkowitz Steven W. $30,690 worth of CorMedix Inc. (NYSEMKT:CRMD) was bought by Markvicka Taunia.
More news for CorMedix Inc. (NYSEMKT:CRMD) were recently published by: Valuewalk.com, which released: “Resonant Down 70%â€¦ Could CorMedix Inc. (CRMD) Be Next?” on April 13, 2015. Quotes.Wsj.com‘s article titled: “News CorMedix Inc.CRMD” and published on February 11, 2011 is yet another important article.
CRMD Company Profile
CorMedix Inc., incorporated on July 28, 2006, is a commercial pharmaceutical and medical device company. The Firm in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Firm has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.